Cargando…
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
Irreversible Bruton tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib have demonstrated remarkable clinical responses in multiple B-cell malignancies. Acquired resistance has been identified in a sub-population of patients in which mutations affecting BTK predominantly substitute cystein...
Autores principales: | Hamasy, A, Wang, Q, Blomberg, K E M, Mohammad, D K, Yu, L, Vihinen, M, Berglöf, A, Smith, C I E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220130/ https://www.ncbi.nlm.nih.gov/pubmed/27282255 http://dx.doi.org/10.1038/leu.2016.153 |
Ejemplares similares
-
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021) -
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022) -
Lacticin 481 Synthetase as a General Serine/Threonine
Kinase
por: You, Young Ok, et al.
Publicado: (2009) -
Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant
por: Libre, Camille, et al.
Publicado: (2020) -
Correction to Lancet Oncol 2013; 14: 481
Publicado: (2013)